Published: 11 August 2024
Author(s): Mike Du, Francesco Dernie, Martí Català, Antonella Delmestri, Wai Yi Man, James T. Brash, Hanne van Ballegooijen, Núria Mercadé-Besora, Talita Duarte-Salles, Miguel-Angel Mayer, Angela Leis, Juan Manuel Ramírez-Anguita, Romain Griffier, Guillaume Verdy, Albert Prats-Uribe, Alexandra Pacurariu, Daniel R. Morales, Roberto De Lisa, Sara Galluzzo, Gunter F. Egger, Daniel Prieto-Alhambra, Eng Hooi Tan
Section: Original Article
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder of connective tissue with a highly variable clinical presentation, disease course and prognosis [1]. SLE is characterised by periods of remission and flares, and the presence of autoantibodies that target nuclear antigens [2]. The disease is thought to be more severe in childhood-onset SLE (cSLE), with higher prevalence of morbidity and lower survival rates [3].
